Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Drug users targeted in bid to stop hep C transmission

Injecting drug users will be offered a breakthrough treatment for hepatitis C as part of a Melbourne study to assess whether treating them can reduce transmission of the virus in the community.

Published
17 December 2014
From
Sydney Morning Herald
Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug

Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response (SVR). Customers who have an SVR when tested 12 weeks after the completion of treatment are considered cured.

Published
17 December 2014
From
Insurance News Net
Hepatitis C ruled out as cause of mental impairment in HIV patients

“Hepatitis C infection has serious long-term side effects, such as damage to the liver, but our research indicates that it does not affect the brain,” said lead author David Clifford, MD, of Washington University.

Published
15 December 2014
From
Washington University press release
Scaling up screening for viral hepatitis in Europe

A new toolkit on screening for chronic viral hepatitis seeks to raise awareness, improve knowledge and motivate public health professionals in Europe to take action. Knowledge and understanding of what works in screening for chronic hepatitis B/C has now been translated into practical and relevant tools, including videos and animations, to enable others to replicate successful screening programmes among at risk populations in their area.

Published
15 December 2014
From
Medical Xpress
Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

Published
12 December 2014
From
Chimicles & Tikellis press release
Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug

Philadelphia's transit agency has sued Gilead Sciences Inc., accusing the company of "price-gouging" on the sale of its $1,000-per-pill hepatitis C drug Sovaldi, the latest salvo in a battle between health-care payers and the pharmaceutical industry.

Published
11 December 2014
From
Nasdaq
Daclatasvir for hepatitis C: added benefit not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) has concluded that data for patients without cirrhosis of the liver who are infected with hepatitis C virus (HCV) genotype 1, and for patients with HCV genotype 4 are not suitable for proving an added benefit of Daklinza (daclatasvir).

Published
11 December 2014
From
German Institute for Quality and Efficiency in Health Care (IQWiG)
Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97%

Published
10 December 2014
By
Liz Highleyman
Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir) - for the treatment of genotype 1 hepatitis C patients. European approval is expected to occur in early 2015 following a positive recommendation from a European Medicines Agency committee last month. Payers in the US are hoping that AbbVie will deliver festive cheer by announcing a notable 'sticker price' discount versus Gilead Sciences' Harvoni brand, which costs $94,500 for a 12-week supply.

Published
10 December 2014
From
Hepatitis C New Drugs
Pakistani Blood Transfusions Spreading Hepatitis, HIV: Official

Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with hepatitis, a top government health official said on Friday. Some also get HIV.

Published
09 December 2014
From
HepatitisCNewDrugs

Filter by country